Table 2.
Optimal strategies in base case and under a variety of different assumptions with their incremental cost‐effectiveness ratio
| Parameter | Optimum strategy | ICER in € | |
|---|---|---|---|
| Screening age | Interval | ||
| Base case | 55‐64 | 3 | 19 733 |
| Highest utility for screening attendance | 54‐63 | 3 | 17 960 |
| Lowest utility for screening attendance | 55‐64 | 3 | 19 416 |
| Highest utility for diagnostic phase | 55‐64 | 3 | 19 371 |
| Lowest utility for diagnostic phase | 54‐63 | 3 | 18 582 |
| Highest utility for diagnosis | 55‐64 | 3 | 19 615 |
| Lowest utility for diagnosis | 55‐64 | 3 | 19 853 |
| Highest utility at 2 mo after RP treatment | 55‐64 | 3 | 19 284 |
| Lowest utility at 2 mo after RP treatment | 55‐64 | 3 | 19 956 |
| Highest utility at 2 mo after RT treatment | 55‐64 | 3 | 19 516 |
| Lowest utility at 2 mo after RT treatment | 55‐64 | 3 | 19 771 |
| Highest utility at 2 mo to 1 y after RP treatment | 55‐64 | 3 | 18 427 |
| Lowest utility at 2 mo to 1 y after RP treatment | 54‐63 | 3 | 19 427 |
| Highest utility at 2 mo to 1 y after RT treatment | 55‐64 | 3 | 18 835 |
| Lowest utility at 2 mo to 1 y after RT treatment | 54‐63 | 3 | 19 494 |
| Highest utility for AS | 55‐64 | 3 | 17 630 |
| Lowest utility for AS | 55‐61 | 3 | 19 217 |
| Highest utility for postrecovery period | 55‐65 | 2 | 19 150 |
| Lowest utility for postrecovery period | 55‐61 | 3 | 15 816 |
| Highest utility for Palliative therapy | 55‐61 | 3 | 17 085 |
| Lowest utility for Palliative therapy | 55‐67 | 2 | 18 133 |
| Highest utility for terminal illness | 54‐63 | 3 | 18 732 |
| Lowest utility for terminal illness | 55‐64 | 3 | 19 380 |
| Costs of PSA test +20% | 54‐63 | 3 | 18 710 |
| Costs of PSA test −20% | 55‐63 | 2 | 19 472 |
| Costs of invitation +20% | 55‐64 | 3 | 19 673 |
| Costs of invitation −20% | 55‐64 | 3 | 19 794 |
| Costs of biopsy +20% | 54‐63 | 3 | 18 664 |
| Costs of biopsy −20% | 55‐64 | 3 | 19 343 |
| Costs of RP +20% | 55‐64 | 3 | 19 562 |
| Costs of RP −20% | 55‐64 | 3 | 17 697 |
| Costs of RT +20% | 54‐63 | 3 | 19 986 |
| Costs of RT −20% | 55‐64 | 3 | 17 429 |
| Costs of AS +20% | 54‐63 | 3 | 18 710 |
| Costs of AS −20% | 55‐64 | 3 | 19 267 |
| Costs of staging +20% | 55‐64 | 3 | 19 815 |
| Costs of staging −20% | 55‐64 | 3 | 19 651 |
| Costs of follow‐up +20% | 55‐64 | 3 | 19 783 |
| Costs of follow‐up −20% | 55‐64 | 3 | 19 683 |
| Costs of advanced case +20% | 55‐64 | 3 | 18 940 |
| Costs of advanced case −20% | 54‐63 | 3 | 18 989 |
Abbreviations: AS, active surveillance, ICER, incremental cost‐effectiveness ratio, RP, radical prostatectomy; RT, radiation therapy.